CarmenBigles headshot

Carmen I. Bigles
President and CEO
Carmen I. Bigles is President and CEO of Coquí RadioPharmaceuticals, Corp. (Coquí Pharma), a company founded in 2009 with the goal of establishing a medical radioisotope production facility in the United States.

Prior to founding Coquí Pharma, Bigles co-founded and served as Chief Financial Officer of Caribbean Radiation Oncology Center in Puerto Rico. The center is one of the region’s premier medical facilities for advanced oncological radiation technology. Bigles oversaw the $12 million construction of the center’s first facility in Bayamon, Puerto Rico, and ensured the clinic was opened one year ahead of schedule.

It was during her time at Caribbean Radiation Oncology Center that Bigles noticed several patients coming to the clinic not properly diagnosed. She learned that this was the result of the global shortage of Molybdenum-99 (Mo-99). Recognizing that patients’ treatments could be compromised as a result of the shortage, Bigles sought to learn more about the Mo-99 industry and ultimately decided to establish a domestic source of Mo-99, thus founding Coquí RadioPharmaceuticals.

Bigles was born in San Juan, Puerto Rico, and received her education in Florida and Puerto Rico. In 1997, she earned a bachelor’s degree in mathematics from Interamerican University in San Juan and subsequently master’s degrees in architecture and suburban and town planning from the University of Miami in 2000.

Bigles lives in Coral Gables, Florida, with her husband, Dr. Pedro A. Serrano-Ojeda, and their two daughters, Carmen Irene Serrano-Bigles and Caterina Isabel Serrano-Bigles.

Our Support Team

INVAP is an Argentinian nuclear engineering firm that has contracted with Coquí to be the designer and general contractor for construction of the Medical Isotope Production Facility (MIPF). INVAP has been involved in nuclear development for over 30 years, during which it has worked on more than 15 nuclear reactors and related facilities across the world, including several reactors used to produce medical isotopes—namely the OPAL reactor in Australia, the ETRR-2 reactor in Egypt, and the NUR reactor in Algeria. The MIPF will use an open pool reactor technology similar to that employed in the INVAP-designed OPAL facility in Australia.

Hogan Lovells US, LLP
Hogan Lovells is an international law firm with experienced nuclear regulatory and environmental attorneys who will assist Coquí with facility licensing and environmental review. Hogan Lovells is a global legal practice that helps corporations, financial institutions, and governmental entities with their critical business and legal issues. The firm has more than 2,500 lawyers in more than 40 offices in Africa, Asia, Europe, Latin America, the Middle East, and the United States.

Gresham, Smith and Partners
Headquartered in Nashville, Tennessee, GS&P is a comprehensive multi-disciplinary architectural, engineering, and environmental firm with more than 650 employees. GS&P assists private and public sector clients nationally in developing new facilities including design, permitting and environmental reviews. GS&P has contracted with Coquí to assist with site selection, and has primary responsibility for drafting environmental reviews, collecting site data, and preparing the Environmental Report for the Medical Isotope Production Facility applications.

MPR Associates
MPR Associates is a leading nuclear engineering firm that employs more than more than 170 engineers and scientists. The Alexandria, Va.-based firm has been at the forefront of advanced/new nuclear plants for over 20 years and is known for solving technical problems with the client’s point of view in mind. MPR Associates has been contracted by Coquí as the owner’s engineer.